Cumberland Pharma Reports Key Clinical and Business Developments in November 2024
Significant Milestones in Patient Care and Product Development
-
Caldolor® vs. Ketorolac Research: A recent study analyzing 17 million patient records revealed that Caldolor® is associated with fewer adverse drug reactions and better healthcare utilization compared to ketorolac, benefiting over 150,000 adult and pediatric patients.
-
FDA Designations for Ifetroban: The FDA has granted Orphan Drug and Rare Pediatric Disease designations to Ifetroban, aimed at treating Duchenne Muscular Dystrophy. This recognition underscores the urgent need for effective treatments and offers hope to affected families.
-
Advancements in Delirium Treatment: The MENDING Study, a Phase II trial, has shown promising top-line results for a new treatment targeting delirium in critically ill patients, marking a significant step forward in critical care.
-
Innovative Biopharmaceutical Pipeline: Cumberland Emerging Technologies (CET) has entered into a Development Agreement to fund a new product designed to locate internal bleeding sites, further expanding its innovative biopharmaceutical pipeline.
-
Expanded Access to Sancuso®: A revised sampling program for Sancuso®, an oncology support medication, has been launched, broadening access and introducing enhanced patient support services to ensure comprehensive care throughout the treatment journey.
-
Combating Antimicrobial Resistance: With antimicrobial resistance identified as a global health crisis, Cumberland is focusing on bringing Vibativ®, a potent antibiotic with a unique dual method of action, to new markets. Vibativ® is designed to address drug-resistant bacteria, offering a potential solution to the growing resistance crisis.
As Cumberland Pharma looks forward to sharing more accomplishments, the company remains committed to its mission of improving patient care through innovative products and treatments.